Celldex Therapeutics will discontinue its experimental skin-disease drug after failing to meet the main goal and key secondary endpoints in a mid-stage study, a move that sent shares down over 7% in extended trading.
Celldex Therapeutics will discontinue its experimental skin-disease drug after failing to meet the main goal and key secondary endpoints in a mid-stage study, a move that sent shares down over 7% in extended trading.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
